Literature DB >> 6476917

Serum amyloid A protein concentration in progressive systemic sclerosis (scleroderma).

S R Brandwein, T A Medsger, M Skinner, J D Sipe, G P Rodnan, A S Cohen.   

Abstract

Serum amyloid A protein (SAA) concentrations were determined in 62 patients with progressive systemic sclerosis (PSS). Forty-seven patients had normal or slightly elevated SAA levels (less than 1000 ng/ml = micrograms/l), while 15 patients had moderately to markedly elevated SAA levels, similar to those observed in active rheumatoid arthritis (RA) (greater than or equal to 1000 ng/ml = micrograms/l). Five patients with PSS had SAA levels corresponding to those observed in amyloidosis secondary to RA. High SAA was associated with more severe skin thickening and diminished cumulative survival at five years. The rarity of amyloidosis secondary to PSS is unlikely to be related to an intrinsic defect in SAA production.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6476917      PMCID: PMC1001414          DOI: 10.1136/ard.43.4.586

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  10 in total

1.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

2.  Amyloid fibril protein AA: purification and properties of the antigenically related serum component as determined by solid phase radioimmunoassay.

Authors:  J D Sipe; T F Ignaczak; P S Pollock; G G Glenner
Journal:  J Immunol       Date:  1976-04       Impact factor: 5.422

3.  [Pericollagenous amyloid deposits in the skin and internal organs in scleroderma].

Authors:  H Holzmann; G W Korting
Journal:  Klin Wochenschr       Date:  1969-04-01

4.  Alpha-1-antitrypsin in progressive systemic sclerosis.

Authors:  J R Seibold; R M Iammarino; G P Rodnan
Journal:  Arthritis Rheum       Date:  1980-03

5.  The role of macrophages in the acute-phase response: SAA inducer is closely related to lymphocyte activating factor and endogenous pyrogen.

Authors:  M B Sztein; S N Vogel; J D Sipe; P A Murphy; S B Mizel; J J Oppenheim; D L Rosenstreich
Journal:  Cell Immunol       Date:  1981-09-01       Impact factor: 4.868

6.  Scleroderma, amyloidosis, and extensor tendon rupture.

Authors:  H M Horwitz; J D DiBeneditto; S R Allegra; H M Baumann
Journal:  Arthritis Rheum       Date:  1982-09

7.  Scleroderma and amyloidosis.

Authors:  W C Lowe
Journal:  Mil Med       Date:  1969-11       Impact factor: 1.437

8.  D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis.

Authors:  V D Steen; T A Medsger; G P Rodnan
Journal:  Ann Intern Med       Date:  1982-11       Impact factor: 25.391

9.  Immunologic studies of the major nonimmunoglobulin protein of amyloid. I. Identification and partial characterization of a related serum component.

Authors:  M Levin; M Pras; E C Franklin
Journal:  J Exp Med       Date:  1973-08-01       Impact factor: 14.307

10.  Detection of a mediator derived from endotoxin-stimulated macrohpages that induces the acute phase serum amyloid A response in mice.

Authors:  J D Sipe; S N Vogel; J L Ryan; K P McAdam; D L Rosenstreich
Journal:  J Exp Med       Date:  1979-09-19       Impact factor: 14.307

  10 in total
  7 in total

Review 1.  Amyloidosis in the rheumatic diseases.

Authors:  V Dhillon; P Woo; D Isenberg
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

2.  The Immunogenetics of Systemic Sclerosis.

Authors:  Begüm Ünlü; Ümit Türsen; Zeynab Rajabi; Navid Jabalameli; Fateme Rajabi
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

3.  Serum amyloid A induces interleukin-6 in dermal fibroblasts via Toll-like receptor 2, interleukin-1 receptor-associated kinase 4 and nuclear factor-κB.

Authors:  Steven O'Reilly; Rachel Cant; Marzena Ciechomska; James Finnigan; Fiona Oakley; Sophie Hambleton; Jacob M van Laar
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

Review 4.  Toll-like receptors in mediating pathogenesis in systemic sclerosis.

Authors:  L Frasca; R Lande
Journal:  Clin Exp Immunol       Date:  2020-02-21       Impact factor: 4.330

5.  Comparative proteomic analysis of serum from patients with systemic sclerosis and sclerodermatous GVHD. Evidence of defective function of factor H.

Authors:  Cinzia Scambi; Valentina La Verde; Lucia De Franceschi; Giovanni Barausse; Fabio Poli; Fabio Benedetti; Marco Sorio; Francesca Deriu; Paola Roncada; Oscar Bortolami; Francesco Turrini; Paola Caramaschi; Chiara Stranieri; Lisa M Bambara; Domenico Biasi
Journal:  PLoS One       Date:  2010-08-13       Impact factor: 3.240

6.  Serum amyloid A is a marker for pulmonary involvement in systemic sclerosis.

Authors:  Katja Lakota; Mary Carns; Sofia Podlusky; Katjusa Mrak-Poljsak; Monique Hinchcliff; Jungwha Lee; Matija Tomsic; Snezna Sodin-Semrl; John Varga
Journal:  PLoS One       Date:  2015-01-28       Impact factor: 3.240

7.  High acute phase protein levels correlate with pulmonary and skin involvement in patients with diffuse systemic sclerosis.

Authors:  Anna Lis-Święty; Małgorzata Widuchowska; Ligia Brzezińska-Wcisło; Eugeniusz Kucharz
Journal:  J Int Med Res       Date:  2018-03-07       Impact factor: 1.671

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.